[{"id":"7fd8451e-e40a-4b5b-98c2-c1a67ba94776","acronym":"","url":"https://clinicaltrials.gov/study/NCT04192981","created_at":"2021-01-18T20:26:03.024Z","updated_at":"2024-07-02T16:35:09.028Z","phase":"Phase 1","brief_title":"GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases","source_id_and_acronym":"NCT04192981","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PIK3CA • PTEN • AKT1 • PIK3R1 • PIK3CG • PIK3CD • PIK3CB • INPP4B • AKT2 • INPP5D • PIK3C3 • PIK3R2 • PIK3R3","pipe":"","alterations":" ","tags":["PIK3CA • PTEN • AKT1 • PIK3R1 • PIK3CG • PIK3CD • PIK3CB • INPP4B • AKT2 • INPP5D • PIK3C3 • PIK3R2 • PIK3R3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paxalisib (GDC-0084)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 12/06/2019","start_date":" 12/06/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-17"},{"id":"05b7b675-d0e8-4ac1-8f2e-b18c95b14ddf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03206203","created_at":"2021-01-18T15:48:15.968Z","updated_at":"2024-07-02T16:35:24.236Z","phase":"Phase 2","brief_title":"Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer","source_id_and_acronym":"NCT03206203","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" HER-2 • ER • PIK3CA • PGR • BRCA1 • BRCA2 • PTEN • BRCA • INPP4B","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation • PTEN mutation","tags":["HER-2 • ER • PIK3CA • PGR • BRCA1 • BRCA2 • PTEN • BRCA • INPP4B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 08/29/2017","start_date":" 08/29/2017","primary_txt":" Primary completion: 11/30/2022","primary_completion_date":" 11/30/2022","study_txt":" Completion: 11/15/2024","study_completion_date":" 11/15/2024","last_update_posted":"2024-01-08"},{"id":"bb882abd-a09d-45b4-b16d-33846bd77bd9","acronym":"PIKNIC","url":"https://clinicaltrials.gov/study/NCT02506556","created_at":"2021-03-02T12:19:35.132Z","updated_at":"2025-02-25T15:42:30.490Z","phase":"Phase 2","brief_title":"Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer","source_id_and_acronym":"NCT02506556 - PIKNIC","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" EGFR • HER-2 • KRAS • ER • ALK • PIK3CA • PGR • NRAS • PTEN • HRAS • AKT1 • PIK3R1 • INPP4B • PI3K • PIK3R3","pipe":" | ","alterations":" KRAS mutation • ER positive • EGFR mutation • HER-2 negative • PIK3CA mutation • EGFR amplification • ALK mutation","tags":["EGFR • HER-2 • KRAS • ER • ALK • PIK3CA • PGR • NRAS • PTEN • HRAS • AKT1 • PIK3R1 • INPP4B • PI3K • PIK3R3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • ER positive • EGFR mutation • HER-2 negative • PIK3CA mutation • EGFR amplification • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 09/07/2015","start_date":" 09/07/2015","primary_txt":" Primary completion: 10/26/2021","primary_completion_date":" 10/26/2021","study_txt":" Completion: 10/26/2021","study_completion_date":" 10/26/2021","last_update_posted":"2022-08-16"}]